News & Updates
Filter by Specialty:
Show Multimedia Only
![[Infographics] Don’t stop at HF: Screen for ATTR-CM](https://sitmspst.blob.core.windows.net/images/articles/hk-pfi-846md00-d1b264a2-f897-4c73-afcc-be580e8a3ac9-square.png)
Management of DKD: Current knowledge and practical insights
23 Aug 2024
byProf. Ronald Ma, Chinese University of Hong Kong; Dr. Masayuki Yamanouchi, Specialist in Nephrology, Toranomon Hospital, Tokyo, Japan
Diabetic kidney disease (DKD) is a global healthcare burden. At a symposium co-organized by Diabetes Hongkong and Hong Kong Society of Nephrology, Professor Ronald Ma of the Chinese University of Hong Kong discussed the current landscape of DKD in Hong Kong, and Dr Masayuki Yamanouchi, a specialist in nephrology from Toranomon Hospital in Tokyo, Japan, discussed clinical and real-world evidence on the effects of a nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, in improving outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Dr Yamanouchi also presented two patient cases to illustrate the clinical benefits of finerenone in DKD patients with different disease severity.
Management of DKD: Current knowledge and practical insights
23 Aug 2024
Preventing exacerbations across a broad range of severe asthma patients
22 Aug 2024
byDr. Herbert Kwok, Department of Medicine, University of Hong Kong
Preventing exacerbations remains a primary goal in asthma management. In an interview with MIMS Doctor, Dr Herbert Kwok of the Department of Medicine, the University of Hong Kong, discussed challenges in achieving this goal, particularly in patients with difficult-to-treat type 2 (T2)–low disease, and shared real-world cases from his practice. He also offered insights into the role of airway hyperresponsiveness (AHR) in asthma and explained how blocking thymic stromal lymphopoietin (TSLP) with tezepelumab can prevent exacerbations and improve AHR across a broad range of severe asthma patients.
